Muhammad Arif Lodhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Muhammad Arif Lodhi has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Ajmal Khan
Natural and Medical Sciences Research Center, University of Nizwa, Nizwa, Oman
3 shared publications Farida Begum
Oujiang Laboratory (Zhejiang Laboratory for Regenerative Medicine, Vision, and Brain Health), Wenzhou, Zhejiang, P.R. China
3 shared publications- Ahmed Al-Harrasi
Natural and Medical Sciences Research Center, University of Nizwa, Nizwa 616, Oman
2 shared publications Sajid Iqbal
Oujiang Laboratory (Zhejiang Laboratory for Regenerative Medicine, Vision, and Brain Health), Wenzhou, Zhejiang, P.R. China
2 shared publicationsAbdul Wadood
Dr Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan
1 shared publicationAlanood S. Algarni
Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 29 July 2025
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 18, 952025-9
Investigating the potential of novel thiazolidinone derivatives as anti-alzheimer agents: A comprehensive study through kinetics, in silico, and in vitro approaches
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by behavior, memory, and cognitive impairment. Acetylcholinesterase (AChE) is primarily responsible for acetylcholine (ACh) breakdown and is considered a leading cause of AD. The current study was designed to assess thiazolidinone compounds (1-12) as synthetic inhibitors of AChE as potential therapeutic options for AD. For this purpose, inhibitory activities, kinetics analysis, antispasmodic potential, and molecular dynamic (MD) simulations were conducted for 12 newly synthesized thiazolidinone compounds. The results demonstrate significant inhibition of AChE (IC50 ranging from 209.53 ± 1.01 µM to 1656.01 ± 1.60 µM) by all tested compounds. Kinetic analysis revealed that these compounds bind to the allosteric site and reduce AChE proficiency. The non-competitive nature of these compounds is an important finding that suggests that they could effectively reduce ACh hydrolysis even at high substrate concentrations. The obtained molecular docking results suggested that these compounds formed π-π stacking and hydrogen bonding interactions with the anionic sub-site and peripheral anionic site (PAS) of AChE. Their inhibitory efficacy is supported by this structural insight, which also helps in identifying important interactions for future optimization. MD simulation showed that the interaction of selected compounds 12 and 3 with AChE remains stable during simulations. This highlights their potential as effective therapeutic agents. Additionally, the whole series displayed calcium (Ca2+) antagonistic and antispasmodic potential, which could contribute to their therapeutic impacts beyond the inhibition of AChE. Among all tested compounds, compounds 12 and 3 demonstrated the highest proficiency in countering spontaneous and potassium (K+)-induced spasms. Therefore, the anti-AChE activity, Ca2⁺ antagonistic abilities, and safety profile of these compounds position them as potential multi-target drug candidates for AD and its related complications in the future.
- 29 July 2025
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 18, 952025-9
Open AccessInvestigating the potential of novel thiazolidinone derivatives as anti-alzheimer agents: A comprehensive study through kinetics, in silico, and in vitro approaches
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by behavior, memory, and cognitive impairment. Acetylcholinesterase (AChE) is primarily responsible for acetylcholine (ACh) breakdown and is considered a leading cause of AD. The current study was designed to assess thiazolidinone compounds (1-12) as synthetic inhibitors of AChE as potential therapeutic options for AD. For this purpose, inhibitory activities, kinetics analysis, antispasmodic potential, and molecular dynamic (MD) simulations were conducted for 12 newly synthesized thiazolidinone compounds. The results demonstrate significant inhibition of AChE (IC50 ranging from 209.53 ± 1.01 µM to 1656.01 ± 1.60 µM) by all tested compounds. Kinetic analysis revealed that these compounds bind to the allosteric site and reduce AChE proficiency. The non-competitive nature of these compounds is an important finding that suggests that they could effectively reduce ACh hydrolysis even at high substrate concentrations. The obtained molecular docking results suggested that these compounds formed π-π stacking and hydrogen bonding interactions with the anionic sub-site and peripheral anionic site (PAS) of AChE. Their inhibitory efficacy is supported by this structural insight, which also helps in identifying important interactions for future optimization. MD simulation showed that the interaction of selected compounds 12 and 3 with AChE remains stable during simulations. This highlights their potential as effective therapeutic agents. Additionally, the whole series displayed calcium (Ca2+) antagonistic and antispasmodic potential, which could contribute to their therapeutic impacts beyond the inhibition of AChE. Among all tested compounds, compounds 12 and 3 demonstrated the highest proficiency in countering spontaneous and potassium (K+)-induced spasms. Therefore, the anti-AChE activity, Ca2⁺ antagonistic abilities, and safety profile of these compounds position them as potential multi-target drug candidates for AD and its related complications in the future.
- Open Access
- 27 November 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (49) , 46816-46829
Inhibition of Acetylcholinesterase with Novel 1, 3, 4, Oxadiazole Derivatives: A Kinetic, In Silico, and In Vitro Approach
Alzheimer's disease (AD) is a neurological disease that disturbs the memory, thinking skills, and behavior of the affected person. AD is a complex disease caused by the breakdown of acetylcholine via acetylcholinesterase (AChE). The present study aimed to assess the synthetic inhibitors of AChE that could be used to treat AD. For this purpose, synthetic compounds of oxadiazole derivatives (15-35) were evaluated and identified as promising inhibitors of AChE, exhibiting IC50 varying between 41.87 ± 0.67 and 1580.25 ± 0.7 μM. The kinetic parameters indicated that all the studied compounds bind to the allosteric site and decrease the efficiency of the AChE enzyme. In silico docking analysis showed that the majority of the compounds interact with the anionic subsite and Per-Arnt-Sim domain of AChE and are stabilized by various bonds including π-π and hydrogen bonding. The stability of the most potent compounds 16 and 17 with AChE interaction was confirmed by molecular dynamics simulations. Moreover, all compounds exhibited concentration-dependent calcium (Ca2+) antagonistic and spasmolytic activities. Among the whole series of oxadiazole derivatives, compounds 16 and 17 displayed the highest activities on spontaneous and potassium (K+)-induced contraction. Therefore, the AChE inhibitory potential, cytotoxicity safe profile, and Ca2+ antagonistic ability of these compounds make them potential therapeutic agents against AD and its associated problems in the future.
- 27 November 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (49) , 46816-46829
Open AccessInhibition of Acetylcholinesterase with Novel 1, 3, 4, Oxadiazole Derivatives: A Kinetic, In Silico, and In Vitro Approach
Alzheimer's disease (AD) is a neurological disease that disturbs the memory, thinking skills, and behavior of the affected person. AD is a complex disease caused by the breakdown of acetylcholine via acetylcholinesterase (AChE). The present study aimed to assess the synthetic inhibitors of AChE that could be used to treat AD. For this purpose, synthetic compounds of oxadiazole derivatives (15-35) were evaluated and identified as promising inhibitors of AChE, exhibiting IC50 varying between 41.87 ± 0.67 and 1580.25 ± 0.7 μM. The kinetic parameters indicated that all the studied compounds bind to the allosteric site and decrease the efficiency of the AChE enzyme. In silico docking analysis showed that the majority of the compounds interact with the anionic subsite and Per-Arnt-Sim domain of AChE and are stabilized by various bonds including π-π and hydrogen bonding. The stability of the most potent compounds 16 and 17 with AChE interaction was confirmed by molecular dynamics simulations. Moreover, all compounds exhibited concentration-dependent calcium (Ca2+) antagonistic and spasmolytic activities. Among the whole series of oxadiazole derivatives, compounds 16 and 17 displayed the highest activities on spontaneous and potassium (K+)-induced contraction. Therefore, the AChE inhibitory potential, cytotoxicity safe profile, and Ca2+ antagonistic ability of these compounds make them potential therapeutic agents against AD and its associated problems in the future.
- Open Access
- 9 August 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 946134
2-Mercaptobenzimidazole clubbed hydrazone for Alzheimer’s therapy: In vitro, kinetic, in silico, and in vivo potentials
Alzheimer’s is a type of dementia that affects the affected person’s thinking, memory, and behavior. It is a multifactorial disease, developed by the breakdown of the neurotransmitter acetylcholine via acetylcholinesterase (AChE). The present study was designed to evaluate potential inhibitors of acetylcholinesterase that could be used as a therapeutic agent against Alzheimer’s disease (AD). For this course, synthetic compounds of the Schiff bases class of 2-mercaptobenzimidazole hydrazone derivatives (9–14) were determined to be potent acetylcholinesterase inhibitors with IC50 values varying between 37.64 ± 0.2 and 74.76 ± 0.3 μM. The kinetic studies showed that these are non-competitive inhibitors of AChE. Molecular docking studies revealed that all compounds accommodate well in the active site and are stabilized by hydrophobic interactions and hydrogen bonding. Molecular dynamics (MD) simulations of selected potent inhibitors confirm their stability in the active site of the enzyme. Moreover, all compounds showed antispasmodic and Ca2+ antagonistic activities. Among the selected compounds of 2-mercaptobenzimidazole hydrazone derivatives, compound 11 exhibited the highest activity on spontaneous and K+-induced contractions, followed by compound 13. Therefore, the Ca2+ antagonistic, AChE inhibition potential, and safety profile of these compounds in the human neutrophil viability assay make them potential drug candidates against AD in the future.
- 9 August 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 946134
Open Access2-Mercaptobenzimidazole clubbed hydrazone for Alzheimer’s therapy: In vitro, kinetic, in silico, and in vivo potentials
Alzheimer’s is a type of dementia that affects the affected person’s thinking, memory, and behavior. It is a multifactorial disease, developed by the breakdown of the neurotransmitter acetylcholine via acetylcholinesterase (AChE). The present study was designed to evaluate potential inhibitors of acetylcholinesterase that could be used as a therapeutic agent against Alzheimer’s disease (AD). For this course, synthetic compounds of the Schiff bases class of 2-mercaptobenzimidazole hydrazone derivatives (9–14) were determined to be potent acetylcholinesterase inhibitors with IC50 values varying between 37.64 ± 0.2 and 74.76 ± 0.3 μM. The kinetic studies showed that these are non-competitive inhibitors of AChE. Molecular docking studies revealed that all compounds accommodate well in the active site and are stabilized by hydrophobic interactions and hydrogen bonding. Molecular dynamics (MD) simulations of selected potent inhibitors confirm their stability in the active site of the enzyme. Moreover, all compounds showed antispasmodic and Ca2+ antagonistic activities. Among the selected compounds of 2-mercaptobenzimidazole hydrazone derivatives, compound 11 exhibited the highest activity on spontaneous and K+-induced contractions, followed by compound 13. Therefore, the Ca2+ antagonistic, AChE inhibition potential, and safety profile of these compounds in the human neutrophil viability assay make them potential drug candidates against AD in the future.
- 27 October 2021
- Published by Springer Nature in Pharmaceutical Chemistry Journal
- Vol. 55 (7) , 665-678
Synthesis, Pharmacological Evaluation and Molecular Docking Studies of N-[2-(1H-indol-3-yl)Acetyl]Arylsulfonohydrazides
- 27 October 2021
- Published by Springer Nature in Pharmaceutical Chemistry Journal
- Vol. 55 (7) , 665-678
Synthesis, Pharmacological Evaluation and Molecular Docking Studies of N-[2-(1H-indol-3-yl)Acetyl]Arylsulfonohydrazides
- 1 January 2021
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 30 (1) , 120-132
Dihydropyrimidones: A ligands urease recognition study and mechanistic insight through in vitro and in silico approach
- 1 January 2021
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 30 (1) , 120-132
Dihydropyrimidones: A ligands urease recognition study and mechanistic insight through in vitro and in silico approach
- 4 March 2017
- Published by Taylor & Francis in Hemoglobin
- Vol. 41 (2) , 104-109
Population-Based Genetic Study of β-Thalassemia Mutations in Mardan Division, Khyber Pakhtunkhwa Province, Pakistan
β-Thalassemia (β-thal) is the most prevalent hereditary blood disorder in Pakistan with a carrier rate of 5.0–8.0%. The homozygous affected children require frequent blood transfusions for their survival. This autosomal recessive disease can only be prevented through awareness programs, carrier screening, mutation detection, genetic counseling and prenatal diagnosis (PND). The present study aimed to determine the prevalence of various mutations causing β-thal and also to detect carriers of these mutations in families living in the Mardan Division, Khyber Pakhtunkhwa (KP) Province, Pakistan. The study was conducted at the Department of Biochemistry, Abdul Wali Khan University Mardan, Pakistan. Blood samples of β-thalassemic families were collected from various transfusion centers in Mardan Division. Using the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) technique, all samples were analyzed for the six most common mutations causing β-thal in this area. Six different mutant primers for the detection of different mutations were used. The most common mutations detected in thalassemic patients were frameshift codons (FSC) 8/9 (+G) (HBB: c.27_28insG), codons 41/42 (–TTCT) (HBB: c.126_129delCTTT), and IVS-I-5 (G>C) (HBB: c.92+5G>C). The predominant mutation for carrying the mutant genes for β-thal were FSC 8/9, IVS-I-5, codons 41/42, IVS-I-1. It was also found that 66.7% of marriages were consanguineous. The FSC 8/9 mutation was found to be the most common β-thal mutation with a frequency of 44.4%. This research project provides a strong incentive for the establishment of large scale mutation detection and PND services in the Mardan Division.
- 4 March 2017
- Published by Taylor & Francis in Hemoglobin
- Vol. 41 (2) , 104-109
Population-Based Genetic Study of β-Thalassemia Mutations in Mardan Division, Khyber Pakhtunkhwa Province, Pakistan
β-Thalassemia (β-thal) is the most prevalent hereditary blood disorder in Pakistan with a carrier rate of 5.0–8.0%. The homozygous affected children require frequent blood transfusions for their survival. This autosomal recessive disease can only be prevented through awareness programs, carrier screening, mutation detection, genetic counseling and prenatal diagnosis (PND). The present study aimed to determine the prevalence of various mutations causing β-thal and also to detect carriers of these mutations in families living in the Mardan Division, Khyber Pakhtunkhwa (KP) Province, Pakistan. The study was conducted at the Department of Biochemistry, Abdul Wali Khan University Mardan, Pakistan. Blood samples of β-thalassemic families were collected from various transfusion centers in Mardan Division. Using the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) technique, all samples were analyzed for the six most common mutations causing β-thal in this area. Six different mutant primers for the detection of different mutations were used. The most common mutations detected in thalassemic patients were frameshift codons (FSC) 8/9 (+G) (HBB: c.27_28insG), codons 41/42 (–TTCT) (HBB: c.126_129delCTTT), and IVS-I-5 (G>C) (HBB: c.92+5G>C). The predominant mutation for carrying the mutant genes for β-thal were FSC 8/9, IVS-I-5, codons 41/42, IVS-I-1. It was also found that 66.7% of marriages were consanguineous. The FSC 8/9 mutation was found to be the most common β-thal mutation with a frequency of 44.4%. This research project provides a strong incentive for the establishment of large scale mutation detection and PND services in the Mardan Division.
- Open Access
- 2 December 2011
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 79 (4) , 431-441
A Novel Pharmacophore Model to Identify Leads for Simultaneous Inhibition of Anti‐coagulation and Anti‐inflammatory Activities of Snake Venom Phospholipase A2
In addition to catalytic action, snake venom phospholipase A2 induces several pharmacological effects including neurotoxicity, cardiotoxicity as well as anti‐coagulant and anti‐platelet aggregation effects. Therefore, strategy to identify dual inhibitor for this enzyme will be of much importance in medical research. In this paper, structure‐based pharmacophore mapping, molecular docking, protein–ligand interaction fingerprints, binding energy calculations, and binding affinity predictions were employed in a virtual screening strategy to identify new hits for dual inhibition of anti‐coagulation and inflammation of phospholipase A2. A structure‐based pharmacophore map was modeled which comprised of important interactions as observed in co‐crystal of phospholipase A2 and its dual inhibitor indomethacin. The generated model was used to retrieve molecules from ChemBridge, a free database of commercially available compounds. A total of 381 molecules mapped on the developed pharmacophore model from ChemBridge database. The hits retrieved were further screened by molecular docking, protein–ligand interaction fingerprints, binding energy calculations, and binding affinity predictions using Genetic Optimization for Ligand Docking and moe. Based on these results, 32 chemo‐types molecules were predicted as potential lead scaffolds for developing novel, potent and structurally diverse dual inhibitor of phospholipase A2.
- 2 December 2011
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 79 (4) , 431-441
Open AccessA Novel Pharmacophore Model to Identify Leads for Simultaneous Inhibition of Anti‐coagulation and Anti‐inflammatory Activities of Snake Venom Phospholipase A2
In addition to catalytic action, snake venom phospholipase A2 induces several pharmacological effects including neurotoxicity, cardiotoxicity as well as anti‐coagulant and anti‐platelet aggregation effects. Therefore, strategy to identify dual inhibitor for this enzyme will be of much importance in medical research. In this paper, structure‐based pharmacophore mapping, molecular docking, protein–ligand interaction fingerprints, binding energy calculations, and binding affinity predictions were employed in a virtual screening strategy to identify new hits for dual inhibition of anti‐coagulation and inflammation of phospholipase A2. A structure‐based pharmacophore map was modeled which comprised of important interactions as observed in co‐crystal of phospholipase A2 and its dual inhibitor indomethacin. The generated model was used to retrieve molecules from ChemBridge, a free database of commercially available compounds. A total of 381 molecules mapped on the developed pharmacophore model from ChemBridge database. The hits retrieved were further screened by molecular docking, protein–ligand interaction fingerprints, binding energy calculations, and binding affinity predictions using Genetic Optimization for Ligand Docking and moe. Based on these results, 32 chemo‐types molecules were predicted as potential lead scaffolds for developing novel, potent and structurally diverse dual inhibitor of phospholipase A2.